Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

HIV Infection

Free Subscription Articles published in Lancet Infect Dis Retrieve available abstracts of 139 articles: HTML format

Single Articles

September 2024
1. HOLT E
   Setbacks and advances in the global HIV response.
   Lancet Infect Dis. 2024;24:e554.
   PubMed    
   
   
   
2. PANNIKOTTU J, Reuter A, Pietersen E, Makhanda G, et al
   Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis.
   Lancet Infect Dis. 2024;24:947-949.
   PubMed    
   
   
   August 2024
3. STARBUCK E
   Biopolitical precarity for women with HIV in South Africa.
   Lancet Infect Dis. 2024 Aug 26:S1473-3099(24)00572.
   PubMed    
   
   
   
4. VANBAELEN T, Manoharan-Basil SS, Kenyon C
   Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance.
   Lancet Infect Dis. 2024 Aug 21:S1473-3099(24)00502.
   PubMed    
   
   
   
5. RACCAGNI AR, Castagna A, Nozza S
   Gonorrhoea and chlamydia screening for asymptomatic people with HIV and HIV PrEP users: open issues.
   Lancet Infect Dis. 2024 Aug 13:S1473-3099(24)00528.
   PubMed    
   
   
   July 2024
6. GRAY GE, Mngadi K, Lavreys L, Nijs S, et al
   Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
   Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00358.
   PubMed     Abstract available
   
   
   
7. LEHMANN C, Schommers P
   The need for novel approaches to HIV-1 vaccine development.
   Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00398.
   PubMed    
   
   
   June 2024
8. DECROO T, Mesic A, Decuyper I
   Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis.
   Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00294.
   PubMed    
   
   
   
9. KOROTYCH O, Achar J, Gurbanova E, Hovhannesyan A, et al
   Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
   Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00228.
   PubMed     Abstract available
   
   
   
10. JOSEPH DAVEY D, de Voux A, Hlatshwayo L, Nelson A, et al
    Prevention of congenital syphilis within antenatal PrEP services in South Africa: missed opportunities.
    Lancet Infect Dis. 2024;24:571-572.
    PubMed    
    
    
    May 2024
11. KITYO C, Mambule IK, Musaazi J, Sokhela S, et al
    Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
    Lancet Infect Dis. 2024 May 28:S1473-3099(24)00289.
    PubMed     Abstract available
    
    
    
12. MOLINA JM, Bercot B, Assoumou L, Rubenstein E, et al
    Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design.
    Lancet Infect Dis. 2024 May 23:S1473-3099(24)00236.
    PubMed     Abstract available
    
    
    
13. CEVIK M, Thompson LC, Upton C, Rolla VC, et al
    Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Lancet Infect Dis. 2024 May 17:S1473-3099(24)00223.
    PubMed     Abstract available
    
    
    April 2024
14. JIN SL, Kolis J, Parker J, Proctor DA, et al
    Social histories of public health misinformation and infodemics: case studies of four pandemics.
    Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
    PubMed     Abstract available
    
    
    
15. 
    Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
    PubMed     Abstract available
    
    
    
16. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
    Plasma-based antigen persistence in the post-acute phase of COVID-19.
    Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
    PubMed    
    
    
    March 2024
17. CHAKAYA J, Fatma R, Cader M, Harries AD, et al
    Post-tuberculosis lung disease: is there a light at the end of tunnel?
    Lancet Infect Dis. 2024 Mar 22:S1473-3099(24)00136.
    PubMed    
    
    
    
18. NAIDOO K, Perumal R, Cox H, Mathema B, et al
    The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience.
    Lancet Infect Dis. 2024 Mar 22:S1473-3099(24)00144.
    PubMed     Abstract available
    
    
    
19. LADHANI SN, White PJ, Campbell H, Mandal S, et al
    Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.
    Lancet Infect Dis. 2024 Mar 20:S1473-3099(24)00031.
    PubMed     Abstract available
    
    
    
20. 
    Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
    PubMed     Abstract available
    
    
    
21. STUCK L, Klinkenberg E, Abdelgadir Ali N, Basheir Abukaraig EA, et al
    Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis.
    Lancet Infect Dis. 2024 Mar 12:S1473-3099(24)00011.
    PubMed     Abstract available
    
    
    
22. COHN J, Mendelson M, Kanj SS, Shafiq N, et al
    Accelerating antibiotic access and stewardship: a new model to safeguard public health.
    Lancet Infect Dis. 2024 Mar 11:S1473-3099(24)00070.
    PubMed     Abstract available
    
    
    
23. DAS M
    UNICEF report reveals gender gaps persist in HIV.
    Lancet Infect Dis. 2024;24:e159.
    PubMed    
    
    
    February 2024
24. ALLAN-BLITZ LT, Fifer H, Klausner JD
    Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions.
    Lancet Infect Dis. 2024 Feb 14:S1473-3099(24)00001.
    PubMed     Abstract available
    
    
    
25. BISBAS G
    Remembering women in the fight against AIDS.
    Lancet Infect Dis. 2024;24:124.
    PubMed    
    
    
    January 2024
26. GONZALEZ R, Nhampossa T, Mombo-Ngoma G, Mischlinger J, et al
    Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2024 Jan 12:S1473-3099(23)00738.
    PubMed     Abstract available
    
    
    
27. REIMCHE JL, Pham CD, Joseph SJ, Hutton S, et al
    Novel strain of multidrug non-susceptible Neisseria gonorrhoeae in the USA.
    Lancet Infect Dis. 2024 Jan 9:S1473-3099(23)00785.
    PubMed    
    
    
    
28. KOSUGI Y, Kaku Y, Hinay AA Jr, Guo Z, et al
    Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00784.
    PubMed    
    
    
    
29. SAMARASEKERA U
    New guidance on infections in people who inject drugs.
    Lancet Infect Dis. 2024;24:e19.
    PubMed    
    
    
    December 2023
30. MATHUR P, Kottilil S
    Novel oral polio vaccine for serotype 2: new hope.
    Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00549.
    PubMed    
    
    
    
31. GANDHI M
    Post-viral sequelae of COVID-19 and influenza.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00762.
    PubMed    
    
    
    
32. ZUMLA A, Benn CS, Bockarie M, Grewal HMS, et al
    Evolution of a strategic, transformative Europe-Africa Global Health partnership-EDCTP3.
    Lancet Infect Dis. 2023 Dec 1:S1473-3099(23)00737.
    PubMed    
    
    
    November 2023
33. DUARTE-NETO AN, Goncalves AM, Eliodoro RHA, Martins WD, et al
    Main autopsy findings of visceral involvement by fatal mpox in patients with AIDS: necrotising nodular pneumonia, nodular ulcerative colitis, and diffuse vasculopathy.
    Lancet Infect Dis. 2023;23:1218-1222.
    PubMed    
    
    
    
34. TAHA AM, Rodriguez-Morales AJ, Sah R
    Mpox breakthrough infections: concerns and actions.
    Lancet Infect Dis. 2023;23:1216-1218.
    PubMed    
    
    
    October 2023
35. OLBRICH L, Verghese VP, Franckling-Smith Z, Sabi I, et al
    Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.
    Lancet Infect Dis. 2023 Oct 30:S1473-3099(23)00491.
    PubMed     Abstract available
    
    
    
36. TRKOLA A, Moore PL
    Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccines.
    Lancet Infect Dis. 2023 Oct 23:S1473-3099(23)00481.
    PubMed     Abstract available
    
    
    September 2023
37. PINNETTI C, Cimini E, Mazzotta V, Matusali G, et al
    Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00482.
    PubMed     Abstract available
    
    
    
38. SCHILLING WHK, Jittamala P, Watson JA, Boyd S, et al
    Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00493.
    PubMed     Abstract available
    
    
    
39. URIU K, Ito J, Kosugi Y, Tanaka YL, et al
    Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.
    Lancet Infect Dis. 2023 Sep 18:S1473-3099(23)00575.
    PubMed    
    
    
    
40. KAKU Y, Kosugi Y, Uriu K, Ito J, et al
    Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5.
    Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00553.
    PubMed    
    
    
    
41. SHERWOOD-MARTIN H
    Aging with HIV in sub-Saharan Africa.
    Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00570.
    PubMed    
    
    
    
42. ZHANG XS, Mandal S, Mohammed H, Turner C, et al
    Transmission dynamics and effect of control measures on the 2022 outbreak of mpox among gay, bisexual, and other men who have sex with men in England: a mathematical modelling study.
    Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00451.
    PubMed     Abstract available
    
    
    
43. LITVINJENKO S, Magwood O, Wu S, Wei X, et al
    Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews.
    Lancet Infect Dis. 2023 Sep 8:S1473-3099(23)00372.
    PubMed     Abstract available
    
    
    
44. HAZRA A, Zucker J, Bell E, Flores J, et al
    Mpox in people with past infection or a complete vaccination course: a global case series.
    Lancet Infect Dis. 2023 Sep 4:S1473-3099(23)00492.
    PubMed     Abstract available
    
    
    
45. JESUDASON T
    Global progress reported for AIDS.
    Lancet Infect Dis. 2023;23:e342.
    PubMed    
    
    
    
46. THE LANCET INFECTIOUS DISEASES
    Negligible role of suppressed HIV in sexual transmission.
    Lancet Infect Dis. 2023;23:983.
    PubMed    
    
    
    August 2023
47. DAS R, Blazquez-Gamero D, Bernstein DI, Gantt S, et al
    Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Lancet Infect Dis. 2023 Aug 31:S1473-3099(23)00343.
    PubMed     Abstract available
    
    
    
48. FAUST L, Naidoo P, Caceres-Cardenas G, Ugarte-Gil C, et al
    Improving measurement of tuberculosis care cascades to enhance people-centred care.
    Lancet Infect Dis. 2023 Aug 28:S1473-3099(23)00375.
    PubMed     Abstract available
    
    
    
49. OGOINA D, Dalhat MM, Denue BA, Okowa M, et al
    Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study.
    Lancet Infect Dis. 2023 Aug 22:S1473-3099(23)00427.
    PubMed     Abstract available
    
    
    
50. ASHLEY-NORMAN P
    A holistic approach to HIV management.
    Lancet Infect Dis. 2023 Aug 16:S1473-3099(23)00544.
    PubMed    
    
    
    
51. GRANT R, Benamouzig D, Catton H, Cheng VC, et al
    COVID-19 pandemic: a catalyst for accelerating global action on patient safety.
    Lancet Infect Dis. 2023 Aug 9:S1473-3099(23)00485.
    PubMed    
    
    
    
52. HERRERA K, Lyang J, Holly T, Faherty EA, et al
    Extragenital gonorrhoea, chlamydia, and HIV co-infection in people with mpox.
    Lancet Infect Dis. 2023 Aug 4:S1473-3099(23)00483.
    PubMed    
    
    
    
53. OUK V, Pham CD, Wi T, van Hal SJ, et al
    The Enhanced Gonococcal Surveillance Programme, Cambodia.
    Lancet Infect Dis. 2023 Aug 4:S1473-3099(23)00479.
    PubMed    
    
    
    July 2023
54. VENKATESAN P
    Statin use in people living with HIV.
    Lancet Infect Dis. 2023;23:789.
    PubMed    
    
    
    June 2023
55. KOREN MA, Lin L, Eckels KH, De La Barrera R, et al
    Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Lancet Infect Dis. 2023 Jun 27:S1473-3099(23)00192.
    PubMed     Abstract available
    
    
    
56. TEICHER A
    Super-spreaders: a historical review.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00183.
    PubMed     Abstract available
    
    
    
57. DUBE K, Morton T, Fox L, Dee L, et al
    A partner protection package for HIV cure-related trials involving analytical treatment interruptions.
    Lancet Infect Dis. 2023 Jun 6:S1473-3099(23)00267.
    PubMed     Abstract available
    
    
    
58. WALIA K, Mendelson M, Kang G, Venkatasubramanian R, et al
    How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
    Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00124.
    PubMed     Abstract available
    
    
    
59. CHEN MY, Williamson DA
    Sexually acquired enteric infections among men who have sex with men.
    Lancet Infect Dis. 2023;23:644-645.
    PubMed    
    
    
    May 2023
60. GARCIA-PRATS AJ, Hoddinott G, Howell P, Hughes J, et al
    Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis.
    Lancet Infect Dis. 2023 May 25:S1473-3099(23)00349.
    PubMed    
    
    
    
61. YAMASOBA D, Uriu K, Plianchaisuk A, Kosugi Y, et al
    Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.
    Lancet Infect Dis. 2023 May 3:S1473-3099(23)00278.
    PubMed    
    
    
    
62. IZU A, Nunes MC, Solomon F, Baillie V, et al
    All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study.
    Lancet Infect Dis. 2023 May 1:S1473-3099(23)00200.
    PubMed     Abstract available
    
    
    April 2023
63. KIMATHI D, Juan-Giner A, Orindi B, Grantz KH, et al
    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Lancet Infect Dis. 2023 Apr 28:S1473-3099(23)00114.
    PubMed     Abstract available
    
    
    
64. VENKATESAN P
    HIV vaccine trial failure.
    Lancet Infect Dis. 2023;23:410.
    PubMed    
    
    
    March 2023
65. CROSS GB, Sari IP, Kityo C, Lu Q, et al
    Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
    Lancet Infect Dis. 2023 Mar 23:S1473-3099(23)00067.
    PubMed     Abstract available
    
    
    
66. BERTRAN M, Andrews N, Davison C, Dugbazah B, et al
    Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
    Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00057.
    PubMed     Abstract available
    
    
    
67. CHEMAITELLY H, Ayoub HH, Tang P, Coyle P, et al
    Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.
    Lancet Infect Dis. 2023 Mar 10:S1473-3099(23)00058.
    PubMed     Abstract available
    
    
    
68. BAGCCHI S
    Poland provides HIV care to Ukrainian refugees.
    Lancet Infect Dis. 2023;23:287.
    PubMed    
    
    
    
69. MUSHTAQ A, Kazi F
    Lenacapavir: a new treatment of resistant HIV-1 infections.
    Lancet Infect Dis. 2023;23:286.
    PubMed    
    
    
    February 2023
70. STAFFORD A, Rimmer S, Gilchrist M, Sun K, et al
    Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection.
    Lancet Infect Dis. 2023 Feb 8:S1473-3099(23)00044.
    PubMed     Abstract available
    
    
    
71. YUE C, Song W, Wang L, Jian F, et al
    ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
    Lancet Infect Dis. 2023 Feb 3:S1473-3099(23)00010.
    PubMed    
    
    
    January 2023
72. URIU K, Ito J, Zahradnik J, Fujita S, et al
    Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
    Lancet Infect Dis. 2023 Jan 31:S1473-3099(23)00051.
    PubMed    
    
    
    December 2022
73. FINK DL, Callaby H, Luintel A, Beynon W, et al
    Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study.
    Lancet Infect Dis. 2022 Dec 22:S1473-3099(22)00806.
    PubMed     Abstract available
    
    
    
74. LAKOH S, Kamudumuli PS, Penney ROS, Haumba SM, et al
    Diagnostic capacity for invasive fungal infections in advanced HIV disease in Africa: a continent-wide survey.
    Lancet Infect Dis. 2022 Dec 21:S1473-3099(22)00656.
    PubMed     Abstract available
    
    
    
75. SUNER C, Ubals M, Tarin-Vicente EJ, Mendoza A, et al
    Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain.
    Lancet Infect Dis. 2022 Dec 12:S1473-3099(22)00794.
    PubMed     Abstract available
    
    
    
76. SCHWARZ M, Schwarz C, Mossig E, Lampichler K, et al
    Isolated peritoneal involvement as a primary manifestation of cystic echinococcosis.
    Lancet Infect Dis. 2022;22:1769.
    PubMed    
    
    
    November 2022
77. MOGENSEN TH, Skouboe MK, Molle I
    Successful use of interferon alfa-2a for persistent parvovirus B19 infection.
    Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00685.
    PubMed     Abstract available
    
    
    
78. CHANG CH, Hung JH, Hsu SM
    Ocular toxoplasmosis in a patient with acquired immunodeficiency syndrome.
    Lancet Infect Dis. 2022 Nov 14. pii: S1473-3099(22)00737.
    PubMed    
    
    
    
79. EKE AC, Gebreyohannes RD, Powell AM
    Understanding clinical outcome measures reported in HIV pregnancy studies involving antiretroviral-naive and antiretroviral-experienced women.
    Lancet Infect Dis. 2022 Nov 11. pii: S1473-3099(22)00687.
    PubMed     Abstract available
    
    
    
80. AGRATI C, Cossarizza A, Mazzotta V, Grassi G, et al
    Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study.
    Lancet Infect Dis. 2022 Nov 7. pii: S1473-3099(22)00662.
    PubMed     Abstract available
    
    
    
81. SHARLAND M, Cappello B, Ombajo LA, Bazira J, et al
    The WHO AWaRe Antibiotic Book: providing guidance on optimal use and informing policy.
    Lancet Infect Dis. 2022;22:1528-1530.
    PubMed    
    
    
    October 2022
82. DORON S, Gandhi M
    New boosters are here! Who should receive them and when?
    Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00688.
    PubMed    
    
    
    
83. MADHI SA, Kwatra G, Richardson SI, Koen AL, et al
    Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
    Lancet Infect Dis. 2022 Oct 20. pii: S1473-3099(22)00596.
    PubMed     Abstract available
    
    
    
84. KHOO SH, FitzGerald R, Saunders G, Middleton C, et al
    Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00644.
    PubMed     Abstract available
    
    
    
85. ANGELO KM, Smith T, Camprubi-Ferrer D, Balerdi-Sarasola L, et al
    Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study.
    Lancet Infect Dis. 2022 Oct 7. pii: S1473-3099(22)00651.
    PubMed     Abstract available
    
    
    
86. BAGCCHI S
    Global alliance to tackle HIV in children.
    Lancet Infect Dis. 2022;22:1426.
    PubMed    
    
    
    September 2022
87. PALICH R, Burrel S, Monsel G, Nouchi A, et al
    Viral loads in clinical samples of men with monkeypox virus infection: a French case series.
    Lancet Infect Dis. 2022 Sep 29. pii: S1473-3099(22)00586.
    PubMed     Abstract available
    
    
    
88. JIAN F, Yu Y, Song W, Yisimayi A, et al
    Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.
    Lancet Infect Dis. 2022 Sep 27. pii: S1473-3099(22)00642.
    PubMed    
    
    
    
89. ARORA P, Nehlmeier I, Kempf A, Cossmann A, et al
    Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75.
    Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00591.
    PubMed    
    
    
    
90. ONYEGBU C
    The persistence of HIV stigma in Kenya.
    Lancet Infect Dis. 2022;22:1292.
    PubMed    
    
    
    
91. BURKI T
    Involuntary sterilisation and HIV.
    Lancet Infect Dis. 2022;22:1284.
    PubMed    
    
    
    
92. MARX FM, Hesseling AC, Martinson N, Theron G, et al
    National survey in South Africa reveals high tuberculosis prevalence among previously treated people.
    Lancet Infect Dis. 2022;22:1273.
    PubMed    
    
    
    
93. LAPA D, Carletti F, Mazzotta V, Matusali G, et al
    Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding.
    Lancet Infect Dis. 2022;22:1267-1269.
    PubMed    
    
    
    August 2022
94. RAJASINGHAM R, Govender NP, Jordan A, Loyse A, et al
    The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis.
    Lancet Infect Dis. 2022 Aug 29. pii: S1473-3099(22)00499.
    PubMed     Abstract available
    
    
    
95. ZHAO FH, Wu T, Hu YM, Wei LH, et al
    Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
    Lancet Infect Dis. 2022 Aug 26. pii: S1473-3099(22)00435.
    PubMed     Abstract available
    
    
    
96. SCHWARTZ NG, Hernandez-Romieu AC, Annambhotla P, Filardo TD, et al
    Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report.
    Lancet Infect Dis. 2022 Aug 4. pii: S1473-3099(22)00425.
    PubMed     Abstract available
    
    
    
97. NAZARETH J, Pan D, Martin CA, Barr I, et al
    Is the UK prepared for seasonal influenza in 2022-23 and beyond?
    Lancet Infect Dis. 2022 Aug 3. pii: S1473-3099(22)00503.
    PubMed    
    
    
    
98. BURKI T
    Guidelines for visceral leishmaniasis and HIV co-infection.
    Lancet Infect Dis. 2022;22:1124-1125.
    PubMed    
    
    
    
99. PETERS RPH, Chico RM, Rowley J, Low N, et al
    Estimating the global burden of sexually transmitted infections.
    Lancet Infect Dis. 2022;22:1112-1113.
    PubMed    
    
    
    
100. THE LANCET INFECTIOUS DISEASES
     Reaching the vulnerable without stigma.
     Lancet Infect Dis. 2022;22:1091.
     PubMed    
     
     
     
101. AYLES H, Mureithi L, Simwinga M
     The state of tuberculosis in South Africa: what does the first national tuberculosis prevalence survey teach us?
     Lancet Infect Dis. 2022;22:1094-1096.
     PubMed    
     
     
     July 2022
102. HENTZIEN M, Autran B, Piroth L, Yazdanpanah Y, et al
     A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab.
     Lancet Infect Dis. 2022 Jul 18. pii: S1473-3099(22)00495.
     PubMed    
     
     
     
103. CHARLES H, Prochazka M, Thorley K, Crewdson A, et al
     Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study.
     Lancet Infect Dis. 2022 Jul 6. pii: S1473-3099(22)00370.
     PubMed     Abstract available
     
     
     
104. HERMAN GA, O'Brien MP, Forleo-Neto E, Sarkar N, et al
     Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
     Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00416.
     PubMed     Abstract available
     
     
     
105. GIROMETTI N, Byrne R, Bracchi M, Heskin J, et al
     Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis.
     Lancet Infect Dis. 2022 Jul 1. pii: S1473-3099(22)00411.
     PubMed     Abstract available
     
     
     June 2022
106. COTTON MF, Madhi SA, Luabeya AK, Tameris M, et al
     Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
     Lancet Infect Dis. 2022 Jun 27. pii: S1473-3099(22)00222.
     PubMed     Abstract available
     
     
     
107. TEMFACK E, Lortholary O
     Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa.
     Lancet Infect Dis. 2022 Jun 21. pii: S1473-3099(22)00315.
     PubMed    
     
     
     
108. MASHAU RC, Meiring ST, Quan VC, Nel J, et al
     Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
     Lancet Infect Dis. 2022 Jun 21. pii: S1473-3099(22)00234.
     PubMed     Abstract available
     
     
     
109. YAMASOBA D, Kosugi Y, Kimura I, Fujita S, et al
     Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
     Lancet Infect Dis. 2022 Jun 8. pii: S1473-3099(22)00365.
     PubMed    
     
     
     May 2022
110. CANNON C, Celum C
     Sexually transmissible infection incidence in men who have sex with men using HIV pre-exposure prophylaxis in Australia.
     Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00284.
     PubMed    
     
     
     
111. TRAEGER MW, Guy R, Asselin J, Patel P, et al
     Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
     Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00175.
     PubMed     Abstract available
     
     
     
112. SEGERAL O, Dim B, Durier C, Nhoueng S, et al
     Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.
     Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00206.
     PubMed     Abstract available
     
     
     
113. MOYO S, Ismail F, Van der Walt M, Ismail N, et al
     Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey.
     Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00149.
     PubMed     Abstract available
     
     
     
114. LO NC, Bezerra FSM, Colley DG, Fleming FM, et al
     Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
     Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00221.
     PubMed     Abstract available
     
     
     
115. KELLY JD, Van Ryn C, Badio M, Fayiah T, et al
     Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study.
     Lancet Infect Dis. 2022 May 16. pii: S1473-3099(22)00127.
     PubMed     Abstract available
     
     
     
116. NDJEKA N, Campbell JR, Meintjes G, Maartens G, et al
     Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
     Lancet Infect Dis. 2022 May 2. pii: S1473-3099(21)00811.
     PubMed     Abstract available
     
     
     April 2022
117. STEED D, Collins J, Farris AB, Guarner J, et al
     Haemophagocytic lymphohistiocytosis associated with bartonella peliosis hepatis following kidney transplantation in a patient with HIV.
     Lancet Infect Dis. 2022 Apr 29. pii: S1473-3099(22)00276.
     PubMed     Abstract available
     
     
     
118. YAN X, Jia Z, Zhang B
     Evaluating the risk compensation of HIV/AIDS prevention measures.
     Lancet Infect Dis. 2022;22:447-448.
     PubMed    
     
     
     March 2022
119. COHEN C, Kleynhans J, von Gottberg A, McMorrow ML, et al
     SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
     Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00069.
     PubMed     Abstract available
     
     
     
120. WELKER J, Pulido JD, Catanzaro AT, Malvestutto CD, et al
     Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
     Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00058.
     PubMed     Abstract available
     
     
     
121. NTOUMI F, Nachega JB, Aklillu E, Chakaya J, et al
     World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.
     Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(22)00142.
     PubMed    
     
     
     
122. MUSHTAQ A, Kazi F
     Updates in pre-exposure prophylaxis for HIV.
     Lancet Infect Dis. 2022;22:320.
     PubMed    
     
     
     
123. BAGCCHI S
     Mother-to-child transmission of HIV in Botswana.
     Lancet Infect Dis. 2022;22:319.
     PubMed    
     
     
     February 2022
124. NAIDOO K, Dookie N
     Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?
     Lancet Infect Dis. 2022 Feb 25. pii: S1473-3099(21)00613.
     PubMed     Abstract available
     
     
     
125. DECROO T, van Deun A
     Implications of bedaquiline-resistant tuberculosis.
     Lancet Infect Dis. 2022;22:166-167.
     PubMed    
     
     
     January 2022
126. LANGE C, Bottger EC, Cambau E, Griffith DE, et al
     Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.
     Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00586.
     PubMed     Abstract available
     
     
     
127. SRIDHAR S, Joaquin A, Bonaparte MI, Bueso A, et al
     Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
     Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00764.
     PubMed     Abstract available
     
     
     
128. DE VRIES HJC, de Laat M, Jongen VW, Heijman T, et al
     Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
     Lancet Infect Dis. 2022 Jan 19. pii: S1473-3099(21)00625.
     PubMed     Abstract available
     
     
     
129. KIRBY T
     Long-acting injectable for HIV approved for use in the UK.
     Lancet Infect Dis. 2022;22:26.
     PubMed    
     
     
     December 2021
130. 
     Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
     Lancet Infect Dis. 2021 Dec 23. pii: S1473-3099(21)00751.
     PubMed     Abstract available
     
     
     
131. SAMARASEKERA U
     Minoo Mohraz-Iran's leader in HIV research.
     Lancet Infect Dis. 2021;21:1640.
     PubMed    
     
     
     
132. KIRBY T
     Philippa Musoke-stop mother-to-child HIV transmission.
     Lancet Infect Dis. 2021;21:1641.
     PubMed    
     
     
     November 2021
133. DAWSON Q
     Is violence the only option to obtain health for HIV prisoners?
     Lancet Infect Dis. 2021 Nov 30. pii: S1473-3099(21)00757.
     PubMed    
     
     
     
134. DHANA A, Hamada Y, Kengne AP, Kerkhoff AD, et al
     Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis.
     Lancet Infect Dis. 2021 Nov 17. pii: S1473-3099(21)00387.
     PubMed     Abstract available
     
     
     
135. ISMAIL NA, Omar SV, Moultrie H, Bhyat Z, et al
     Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
     Lancet Infect Dis. 2021 Nov 12. pii: S1473-3099(21)00470.
     PubMed     Abstract available
     
     
     
136. GOLDSTONE SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, et al
     Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
     Lancet Infect Dis. 2021 Nov 12. pii: S1473-3099(21)00327.
     PubMed     Abstract available
     
     
     October 2021
137. KRUTIKOV M, Faust L, Nikolayevskyy V, Hamada Y, et al
     The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-gamma release assays: a systematic review and meta-analysis.
     Lancet Infect Dis. 2021 Oct 1. pii: S1473-3099(21)00261.
     PubMed     Abstract available
     
     
     September 2021
138. RULE R, Mitton B, Govender NP, Hoffmann D, et al
     Spinal epidural abscess caused by Aspergillus spp masquerading as spinal tuberculosis in a person with HIV.
     Lancet Infect Dis. 2021 Sep 29. pii: S1473-3099(20)30979.
     PubMed     Abstract available
     
     
     
139. 
     Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019.
     Lancet Infect Dis. 2021 Sep 23. pii: S1473-3099(21)00449.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.